Our results demonstrated that MYC overexpression sensitized HNSCC cells to the anti-tumor effects of trametinib, as evidenced by the lower IC50 value in JHU22-MYC cells compared to JHU22-LV cells. Here, MYC is linked to head and neck squamous cell carcinoma.